Benzinga | Jan 26, 2022 07:07AM EST

Quest Diagnostics Launches COVID-19 Rapid Antigen Test Through QuestDirect

Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced the availability of an at-home COVID-19 rapid antigen test service for consumer purchase, available through QuestDirect(tm), the company's consumer-initiated testing platform. Through a collaboration with eMed(tm), the new service features proctored telehealth by which a trained technician observes proper sample collection, confirms identity, and certifies results reporting during a telehealth visit.

The offering enables the Abbott BinaxNOW(tm) COVID-19 Ag Card Home Test, a self-administered nasal swab antigen test that provides results in 15 minutes, to be used under observation from a certified telehealth proctor so that the user receives a laboratory report through eMed. The report may be used for international travel, leisure activities, verification of positive results to enable prescription treatment by a physician, and for return to work or school programs as proctored COVID-19 tests are required in some settings*, including under current CDC guidelines for international travelers coming to the U.S. Each test comes with certified telehealth proctoring already enabled for use 24/7, anywhere in the world. Adults and children aged four and up may use the test. Each test kit contains a two-pack of tests for $70 available for purchase through QuestDirect.